Akebia Therapeutics, Inc. (AKBA) Cash Flow Statement
Akebia Therapeutics, Inc. (AKBA) generated $41.6M of operating cash flow over the twelve months to 2026-06-30, spent $1.3M on capital expenditure and had free cash flow of $40.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AKBAAkebia Therapeutics, Inc.Follow AKBA — free
—
Price chart with a free account
- Market cap
- 157.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 4 days
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -97.5 | -257.4 | -110.4 | -253.0 | -73.2 | -23.4 | -40.7 | 68.0 | 41.6 | |
| Capital expenditure | 1.6 | 6.7 | 0.3 | 0.1 | 0.1 | 0.0 | 0.0 | 0.3 | -1.3 | |
| Free cash flow | -99.1 | -264.1 | -110.7 | -253.0 | -73.3 | -23.4 | -40.7 | 67.7 | 40.3 | |
| Stock-based compensation | 19.0 | 11.9 | 24.5 | 22.7 | 17.8 | 9.3 | 7.8 | 11.3 | — |
USD millions · SEC XBRL
Akebia Therapeutics, Inc. — questions
- What is Akebia Therapeutics, Inc.'s operating cash flow?
- $41.6M over the twelve months to 2026-06-30.
- How much does Akebia Therapeutics, Inc. spend on capital expenditure?
- $1.3M over the twelve months to 2026-06-30.
- What is Akebia Therapeutics, Inc.'s free cash flow?
- $40.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Akebia Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.